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Published clinical trials in patients with ischemic diseases show limited benefit
of adult stem cell-based therapy, likely due to their restricted plasticity and com-
mitment towards vascular cell lineage. Here, we have uncovered the potent regen-
erative ability of MesP1/SSEA-1-expressing cardiovascular progenitors enriched
from human embryonic stem cells (hESC). Injection of only 104 hESC-derived
SSEA-1+/MesP1+ cells, or their progeny obtained after treatment with VEGF-A or
PDGF-BB, was effective enough to enhance post-ischemic revascularization in
immunodeficient mice with critical limb ischemia (CLI). However, the rate of
incorporation of hESC-derived SSEA-1+/MesP1+ cells and their derivatives in
ischemic tissues was modest. Alternatively, these cells possessed a unique miR-21
signature that inhibited PTEN thereby activating HIF-1α and the systemic release
of VEGF-A. Targeting Dicer or miR-21 limited cell survival in vivo and inhibited
their pro-angiogenic capacities both in the Matrigel model and in mice with CLI.
Interestingly, we observed an impaired post-ischemic angiogenesis in miR-21
deficient mice suggesting an unrestricted role of miR-21 in this regenerative envi-
ronment. Notably, amongst the inflammatory cell population, miR-21 was highly
expressed in circulating and infiltrated monocytes where it targeted PTEN/HIF-
1α/VEGF-A signaling. As a result, miR-21 deficient mice displayed an impaired
number of infiltrated monocytes and a defective angiogenic phenotype that could
be partially restored by retransplantation of bone marrow-derived cells from wild-
type littermates. Hence, hESC-derived SSEA-1+/MesP1+ cells progenitor cells are
powerful key integrators of therapeutic angiogenesis in ischemic milieu and miR-
21 is instrumental in this process as well as in the orchestration of post-ischemic
vessel growth.
0369
Proepicardial prokineticin receptor –1 (PKR1) as a developmental
link between heart and kidney
Thu Lan Nguyen (1), Mounia Boulberdaa (1), Kyoji Urayama (1), Verda
Bitirim (1), Bernard Geny (2), Pilar Ruiz-Lozano (3), Canan Nebigil (1)
(1) UMR7242, Biotechnologie, Signalisation Cellulair, CNRS/Université de
Strasbourg, Illkirch, France – (2) EA 3072, Institut de Physiologie, Faculté de
Médecine, et Physiologie et Explorations Fonctionnelles-Pôle de pathologie
thoracique, Strasbourg, France – (3) Burnham Institute for Medical Research,
Development and Aging Program, La Jolla, Ca, Etats-Unis
Background: Prokineticin receptor-1 (PKR1), signals play critical roles in
heart and kidney functions. In particular, the systemic mutation of this
receptor results in thinning of the myocardium and hypoplastic kidney. How-
ever, the molecular and cellular mechanisms controlled by PKR1 signaling in
this process are unclear.
Methods and Results: Here, we analyze a tissue-restricted mutations of the
PKR1 gene in the proepicardial lineages (Gata5 and Wt1), and we show that
PKR1 signaling in the proepicardium and its derivatives is required for proper car-
diac and renal morphogenesis. Neonatal mutant mice display impaired prolifera-
tion of epicardial-derived cells in their heart and kidneys. Moreover, we detect
defective coronary and renal arteriogenesis associated with PKR1 deficiency. Epi-
cardial development is dramatically impaired in mutant mice, including failed
expansion of the subepicardial space, blunted invasion of the myocardium, and
impaired differentiation of epicardium-derived cells into coronary endothelial and
smooth muscle cells. Abnormal mitochondria, lipid accumulation in mutant car-
diomyocytes leads to lower contractile response to dobutamine. Impaired prolifer-
ation was observed in both Gata5 and WT1 but apoptosis was observed only WT1
lieage. Adult mutant hearts had abnormal rhythmicity and impaired systolic func-
tions. Hypoplastic kidneys at the neonatal mutants were accompanied with defi-
cient glomerular angiogenesis. Outgrown cell from kidney explants had a
defective vasculogenic cell differentiation. Atrophy and dilated glomerular struc-
ture, abnormal mitochondria, lipid deposition and apoptosis were observed in the
adult mutant kidney.
Conclusions: Our findings provide a mechanistic insight into the roles of
PKR1 signaling in heart and kidney disorders controlling the maturation of
epicardial-derived cell and differentiation in a cell autonomous fashion and
affecting cellular communications in a paracrine fashion. Our mouse models
recapitulate the complex human heart-kidney disorders.
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Coronary vasculature is required to maintain cardiomyocyte survival, via
delivery of oxygen and nutrients, and consequently myocardial architecture and
cardiac function. Ischemic heart disease following myocardial infarction causes
irreversible cell loss and scaring and is a major cause of morbidity and mortality.
Revascularization of injured, ischemic and regenerating organs is essential to
restore organ function and requires the formation of new vessels by the mecha-
nisms of vasculogenesis, angiogenesis or arteriogenesis. With the objective of
studying vascular remodeling during myocardial infarction (MI), we have per-
formed permanent left coronary ligation on Connexin40-GFP (Cx40GFP/+) mice.
Cx40 encodes a gap junction protein and is expressed in endothelial cells of large
vessels. In the heart, Cx40-GFP expression is detected in coronary arteries but not
in veins, capillaries or endocardium. After two weeks of ligation, MI was detected
in left ventricle by echocardiography and anatomical examination of these hearts
revealed the presence of an extensive network of GFP-positive vasculature within
the infarct area. These vessels follow a tortuous route in the remaining ventricular
wall and some communicate with the left ventricular lumen forming a crater cov-
ered with GFP and VEGF-R2 positive endothelial cells at the endocardial surface.
To determine whether these vessels result from neo-vascularization or coronary
artery remodeling, we carried out genetic lineage tracing of coronary endothelial
cells using an inducible Cx40-cre allele. Our results show that GFP positive endo-
thelial cells forming the endocardial carters are not always derived from pre-
existing coronary arteries, suggesting that endocardium may also contribute to the
generation of new vessels during vascular remodeling in the adult heart by angio-
genesis.
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Objective: Prokineticins are potent angiogenic peptides that bind to two G
protein-coupled receptors to initiate their biological effects. We previously
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